Loading
Loading
Research Overview
Luteinising hormone (LH) analogue; binds LH/hCG receptors on Leydig cells to stimulate testosterone biosynthesis and maintain testicular function; used in fertility treatment to trigger ovulation and in male hormone protocols to maintain endogenous testosterone production.
Overview
Human chorionic gonadotropin is a dimeric glycoprotein produced by the syncytiotrophoblast during pregnancy and used as a research tool due to its high affinity for the luteinising hormone receptor (LHR). In male reproductive biology research, hCG has been studied for its ability to stimulate Leydig cell testosterone production through LHR-mediated cAMP signalling. In female reproductive research, hCG serves as an LH-surge surrogate in ovarian stimulation model systems. Preclinical research has used hCG to characterise LHR pharmacology, gonadal steroidogenesis pathways, and reproductive axis biology in laboratory settings.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, human chorionic gonadotropin (hcg) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Luteinising hormone (LH) analogue; binds LH/hCG receptors on Leydig cells to stimulate testosterone biosynthesis and maintain testicular function; used in fertility treatment to trigger ovulation and in male hormone protocols to maintain endogenous testosterone production.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.